Dragon Pharma Store
Buy legit Dragon Pharma steroids, peptides, SARMs, and more directly from the official Dragon Pharma Store.
Lab-Tested & Verified - ensuring quality, purity, and real results.
Dragon Pharma Anabolics
Why Choose Dragon Pharmaceuticals ?
Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech and pharmaceutical company headquartered in Vancouver, Canada, with state-of-the-art production and R&D facilities in Nanjing, China, and a global team of 160 employees.
The company specializes in the development and commercialization of human proteins for therapeutic use, leveraging proprietary DNA vector technology to achieve high yields of premium-quality protein drugs at reduced costs and high margins.
Beyond its leading role in biotech innovation, Dragon Pharmaceuticals is also a trusted manufacturer of pharmaceutical-grade anabolic steroids, peptides, growth hormones (HGH), SARMs, SERMs, and aromatase inhibitors (AIs)—catering to athletes, bodybuilders, and medical professionals seeking reliable performance-enhancing solutions.
Dragon is recognized as one of the world’s largest producers of Epoetin Alfa (EPO), a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. The company’s EPO is approved and marketed for chronic renal failure treatment in China, Egypt, India, and Peru, with additional regulatory submissions underway across Central and Eastern Europe, Southeast Asia, Latin America, and the Middle East.
Pharmaceutical-Grade Quality
All anabolic steroids, peptides, growth hormones, SARMs, SERMs, and aromatase inhibitors are manufactured under GMP-certified standards, ensuring purity, potency, and safety.
Cutting-Edge Innovation
Using proprietary DNA vector technology and state-of-the-art production, Dragon Pharmaceuticals develops high-quality therapeutic proteins and performance-enhancing compounds at competitive prices.
Global Trust & Reliability
With a strong international presence, Dragon Pharmaceuticals supplies trusted pharmaceutical solutions to athletes, bodybuilders, and medical professionals worldwide.
CORPORATE DATA
Founded: Sepetember 1998
Listed: TSX:DDD and OTC BB
Shares Outstanding: 20,331,000
Head Office: Vancouver, Canada
Manufacturing Facility: Nanjing, China
Number of employees: 160
Sales Revenue: US$3.1 million
Approved Product: Erythropoietin(EPO) for use in patients with renal failure
Product in Development: Slow-Release EPO, GTCSF, Human Lusulin, TPO
Clinical Trials in Progress:
- Clinical trials & market approval submission for EPO in surgery patients
- Pivotal Phase II/III studies for EPO in cancer patients to be completed during 2026
GROWTH STRATEGY
Dragon’s business strategy seeks to balance the high-risk and long-term nature of novel drug development with the lower-risk and shorter time-to-revenue potential offered by generic drugs. Our business strategy, outlined below, provide the Company with a distinct competitive advantage.
HIGH YIELD, LOW COST PRODUCTION TECHNOLOGY
Dragon’s proprietary DNA vector technology platform enables the high-efficiency production of therapeutic proteins and performance-enhancing compounds. Our cutting-edge vectors integrate key features that allow for the development of cell lines producing superior-quality proteins with higher yields and significantly lower production costs than competitors. This cost-effective approach strengthens our position as a leading provider of advanced biotechnology and pharmaceutical solutions.
INITIAL FOCUS ON GENERIC DRUGS
To establish a strong financial foundation while minimizing risks typically associated with early-stage biotech companies, Dragon Pharmaceuticals focuses on the development and commercialization of high-demand generic biotechnology drugs. These products, known for their technical complexity and large market potential, provide the financial resources necessary for future innovation.
With revenue generated from generics, Dragon Pharmaceuticals is strategically shifting toward R&D projects, leading to the development of patented drugs, including anabolic steroids, peptides, growth hormones (HGH), SARMs, SERMs, and aromatase inhibitors (AIs)—all with tremendous revenue potential.
LOW COST DEVELOPMENT AND INFRASTRUCTURE
By leveraging our ability to produce pharmaceutical-grade generics, including anabolic steroids, peptides, growth hormones, SARMs, SERMs, and aromatase inhibitors, at a fraction of the cost of competitors, Dragon Pharmaceuticals maximizes operational efficiency. Our strategy involves conducting product development, clinical trials, and large-scale production in China, ensuring lower overhead costs while maintaining top-tier quality standards.
INITIAL ENTRY INTO NON-PATENTED MARKETS
Dragon Pharmaceuticals capitalizes on regulatory efficiencies within China’s State Drug Administration (SDA) to accelerate product approvals. Our initial market entry strategy focuses on China and other non-patented regions, allowing us to generate substantial revenue in emerging markets before expanding into North America, the European Union, and Japan.
Following SDA approval, our international pharmaceutical licensees, who specialize in navigating global regulatory frameworks, oversee the approval process in highly regulated markets, ensuring seamless international expansion. This strategic global approach positions Dragon Pharmaceuticals as a trusted industry leader in both generic biotech and performance-enhancing pharmaceuticals.